trending Market Intelligence /marketintelligence/en/news-insights/trending/CVn4ZHv0SBGAV6ny9KEczQ2 content esgSubNav
In This List

Hikma to cut 200 jobs as part of consolidation of generics facilities

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Hikma to cut 200 jobs as part of consolidation of generics facilities

Hikma Pharmaceuticals PLC CFO Khalid Nabilsi said the company will cut another 200 positions as it consolidates generics manufacturing facilities and U.S. distribution centers, Reuters reported.

The U.K. pharmaceutical company has already cut 200 jobs since it acquired the generics business from Boehringer Ingelheim Corp. in 2016, Nabilsi said.

Earlier, Hikma Pharmaceuticals said earnings for the year ending Dec. 31, 2017, fell 9%, partly due to intense pricing pressure in the U.S.

The U.S. Food and Drug Administration recently upheld its 2017 rejection of Hikma's application for a generic version of GlaxoSmithKline PLC's blockbuster asthma treatment Advair Diskus.